UBS Group’s Eupraxia Pharmaceuticals EPRX Stock Holding History

UBS Group’s Portfolio EPRX Stock Details EPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.43M	Sell	519,211 -243,424	-32%	-$1.68M	﹤0.01%	4564
2026 Q1	$5.52M	Buy	762,635 +542,611	+247%	+$4.37M	﹤0.01%	3982
2025 Q4	$1.66M	Buy	220,024 +124,268	+130%	+$766K	﹤0.01%	5131
2025 Q3	$565K	Buy	95,756 +58,257	+155%	+$317K	﹤0.01%	6002
2025 Q2	$216K	Sell	37,499 -13,700	-27%	-$52.6K	﹤0.01%	6669
2025 Q1	$168K	Buy	51,199 +23,199	+83%	+$80.1K	﹤0.01%	6658
2024 Q4	$88.8K	Sell	28,000 -5,000	-15%	-$14.8K	﹤0.01%	6949
2024 Q3	$86.8K	Buy	33,000 +3,410	+12%	+$8.97K	﹤0.01%	6456
2024 Q2	$76.3K	Buy	+29,590	New	+$82.3K	﹤0.01%	6362

Other funds holding EPRX

BGC

Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

UBS Group's EPRX Position: Q2 2026 in Review

UBS Group reduced its Eupraxia Pharmaceuticals (EPRX) stake by 32% in Q2 2026, selling an estimated $1.68M and leaving 519,211 shares worth $3.43M. The position accounts for ﹤0.01% of the portfolio, ranked #4564.

UBS Group first reported a position in EPRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $5.52M in Q1 2026. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

UBS Group held 519,211 shares of Eupraxia Pharmaceuticals worth $3.43M as of Q2 2026.
UBS Group sold 243,424 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $1.68M.
Eupraxia Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4564 holding.
UBS Group first reported a position in Eupraxia Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
UBS Group's Eupraxia Pharmaceuticals position peaked at $5.52M in Q1 2026.
67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.